ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$18.70 USD
-0.13 (-0.69%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $18.80 +0.10 (0.53%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AVBP 18.70 -0.13(-0.69%)
Will AVBP be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AVBP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AVBP
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Analysts’ Top NA Picks: ArriVent BioPharma, Inc. (AVBP), Rubrik, Inc. Class A (RBRK)
ArriVent BioPharma’s Strategic Alliance for Cancer Drug Development
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab